Processa Pharmaceuticals (PCSA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.89 mm	2.89 mm	2.89 mm	2.89 mm	2.89 mm	2.89 mm
Cash burn (monthly)	2.01 mm	482.14 k	1.14 mm	905.96 k	(no burn)	481.63 k
Cash used (since last report)	5.60 mm	1.34 mm	3.18 mm	2.52 mm	n/a	1.34 mm
Cash remaining	-2.71 mm	1.55 mm	-289.30 k	367.29 k	n/a	1.55 mm
Runway (months of cash)	-1.3	3.2	-0.3	0.4	n/a	3.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

PCSA institutional ownership history Ownership history

55.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	21	24	-12.5%
Opened positions	4	7	-42.9%
Closed positions	7	3	+133.3%
Increased positions	2	4	-50.0%
Reduced positions	6	3	+100.0%

13F shares	Current	Prev Q	Change
Total value	702.98 mm	824.60 mm	-14.7%
Total shares	13.72 mm	13.93 mm	-1.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
David Young	11.44 mm	$45.20 mm	0.0%
Yuhan (usa)	750.00 k	$2.96 mm	0.0%
Walleye Capital	366.64 k	$182.40 mm	-50.0%
Vanguard	361.68 k	$179.94 mm	0.0%
Citadel Advisors	282.84 k	$140.71 mm	NEW
Manchester Management	142.43 k	$819.00 k	0.0%
Geode Capital Management	68.83 k	$34.24 mm	0.0%
Coastal Bridge Advisors	52.50 k	$26.26 mm	0.0%
Renaissance Technologies	45.40 k	$23.00 k	+45.5%
STT State Street	42.79 k	$21.29 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Walleye Capital	366.64 k	-367.32 k	-50.0%
Citadel Advisors	282.84 k	+282.84 k	NEW
Two Sigma Securities	10.70 k	-51.93 k	-82.9%
Raymond James Financial Services Advisors	0.00	-48.95 k	EXIT
Janney Montgomery Scott	0.00	-46.23 k	EXIT
Millennium Management	35.19 k	+35.19 k	NEW
BLK BlackRock	293.00	-29.11 k	-99.0%
Susquehanna International	28.11 k	+28.11 k	NEW
UBS UBS	0.00	-22.46 k	EXIT
Renaissance Technologies	45.40 k	+14.20 k	+45.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PCSA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
3 Sep 24	Baluch Khoso	Restricted Stock Common Stock	Grant	Acquire A	No	No	31,206	31,206
3 Sep 24	Geraldine Pannu	Restricted Stock Common Stock	Grant	Acquire A	No	No	31,206	31,206
3 Sep 24	Neal James R	Restricted Stock Common Stock	Grant	Acquire A	No	No	31,206	31,206
3 Sep 24	Justin W Yorke	Restricted Stock Common Stock	Grant	Acquire A	No	No	31,206	31,206

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

11 Dec 24

Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

10 Dec 24

HC Wainwright & Co. Reiterates Buy on Processa Pharma, Maintains $6 Price Target

5 Dec 24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $6 price target.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

6 Nov 24

Processa Pharma Q3 2024 GAAP EPS $(1.03) Misses $(1.00) Estimate

30 Oct 24

Press releases

From Benzinga Pro

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

2 Oct 24

Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap's safety-efficacy profile and help to define the optimal dosage